
Europe Biosimulation Market Report and Forecast 2024-2032
Description
Europe Biosimulation Market Report and Forecast 2024-2032
Europe Biosimulation Market Report and Forecast 2024-2032
Europe Biosimulation Market Outlook
The global biosimulation market size was valued at USD 3.5 billion in 2023, with Europe holding a significant market share. The market is driven by technological advancements in biosimulation platforms and tools. It is expected to grow at a CAGR of 17.40% during the forecast period of 2024-2032, with the values likely to attain USD 14.1 billion by 2032.
Key Takeaways
- Recent data suggests that 25% of all annual cancer cases occur in Europe, with nearly half of the population at risk of developing cancer at some point in their lives . The rising emphasis on accelerating oncology drug development, fuelled by the growing number of cancer cases, is expected to surge market demand.
- One of the major Europe biosimulation market trends is the increased collaborative initiatives among the key market players to utilize biosimulation platforms in clinical applications. In March 2024 , Exploristics and Exonate Ltd announced a successful collaboration involving the optimisation of clinical trial designs for Exonate’s upcoming Phase IIb study by leveraging Exploristics’ KerusCloud (a simulation-guided study design platform).
- In March 2023, Certara, Inc., announced the launch of Simcyp™ PBPK Simulator Version 22, adding novel and updating existing features of its population-based modeling and simulation platform. The launch of such technologically advanced biosimulation systems is likely to elevate market value.
Biosimulation is a comparatively newer tool in pharmaceutical drug development that enables researchers to simulate complex biological systems. Several leading market players are actively integrating biosimulation software in their drug development pipelines, owing to its ability to predict drug behavior, optimize treatment strategies, and reduce costs and time compared to conventional experiments. Thus, the rising adoption of biosimulation platforms by pharmaceutical and biotechnology companies is significantly contributing to the Europe biosimulation market growth.
Biosimulation can prove helpful in predicting the long-term outcomes of therapies for chronic diseases including cancer. In Europe, with rising prevalence of cancer, predictive models are increasingly utilized to develop effective treatments. Recent data suggests that 25% of all annual cancer cases occur in the region, with nearly half of the population in Europe at risk of developing cancer at some point in their lives (the cumulative risk estimated to be 49.3%). The rising emphasis on accelerating oncology drug development, fuelled by the growing number of cancer cases in the region, is expected to surge the Europe biosimulation market demand.
Increased collaborative initiatives among the prominent market players facilitate the sharing of resources and expertise, enabling the translation of biosimulation research into clinical applications. In March 2024, Exploristics (a United Kingdom-based provider of bio-simulation software and biostatistics services) and Exonate Ltd (a pharmaceutical company in England) announced a successful collaboration involving optimizing the clinical trial design for Exonate’s upcoming Phase IIb study by leveraging Exploristics’ KerusCloud (a simulation-guided study design platform). The companies were able to establish an enhanced study design for Exonate’s lead candidate, EXN407, an investigational topical treatment for retinal vascular diseases, by using KerusCloud. The increased application of such simulation platforms to reduce risks, cost, and duration associated with a clinical study is likely to boost the Europe biosimulation market share in the forecast period.
Technological advancements in biosimulation software enable more accurate predictions of complex biological processes, such as drug metabolism and pharmacodynamics. Continuous improvement and innovation in the existing biosimulation models is poised to fuel market growth. In March 2023, Certara, Inc., a global leader in drug discovery and development through biosimulation technology, announced the launch of Simcyp™ PBPK Simulator Version 22, adding novel and updating existing features of its population-based modeling and simulation platform. The new pharmacokinetics (PBPK) platform has expanded capabilities for a diverse range of populations and therapeutics types, thereby advancing the drug development process. The release of such innovative biosimulation platforms supported by substantial investments from pharmaceutical companies is anticipated to elevate the market value in coming years.
Europe Biosimulation Market Segmentation
Market Breakup by Product Type
- Services
- Software
- Drug Development
- Drug Discovery
- Other Applications
- Subscription Model
- Ownership Model
- Biotechnology and Pharmaceutical Companies
- Research Institutes
- Regulatory Authorities
- Contract Research Organizations
- United Kingdom
- Germany
- France
- Italy
The key features of the market report include patent analysis, grants analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Dassault Systèmes
- Schrödinger
- Physiomics Plc
- Simulations Plus
- Insilico Biotechnology
- Genedata
- Argenx
- CureVac SE
- INOSIM Software GmbH
- Certara
FAQs
- What is the Europe biosimulation market forecast outlook for 2024-2032?
- What are the major factors aiding the Europe biosimulation market demand?
- What are the major Europe biosimulation market trends?
- What is the market segmentation based on the product type?
- What is the market breakup by delivery type?
- What are the major end users of biosimulation?
- What are the applications of biosimulation?
- What is the market segmentation by countries?
- Who are the key players involved in the Europe biosimulation market?
Meta description
The Europe biosimulation market is poised for growth, driven by the expansion of the global market, which was valued at USD 3.5 billion in 2023, and is projected to grow at a CAGR of 16.90% during the forecast period of 2024-2032.
*Please Note:* The report will take 7 business days to complete, after order confirmation.
Table of Contents
140 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Europe Biosimulation Market Overview
- 3.1 Europe Biosimulation Market Historical Value (2017-2023)
- 3.2 Europe Biosimulation Market Forecast Value (2024-2032)
- 4 Europe Biosimulation Market Landscape*
- 4.1 Europe Biosimulation: Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Europe Biosimulation: Product Landscape
- 4.2.1 Analysis by Product Type
- 4.2.2 Analysis by Application
- 5 Europe Biosimulation Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.2.1 Strengths
- 5.2.2 Weaknesses
- 5.2.3 Opportunities
- 5.2.4 Threats
- 5.3 Porter’s Five Forces Model
- 5.3.1 Bargaining Power of Suppliers
- 5.3.2 Bargaining Power of Buyers
- 5.3.3 Threat of New Entrants
- 5.3.4 Threat of Substitutes
- 5.3.5 Degree of Rivalry
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Europe Biosimulation Market Segmentation (2017-2032)
- 6.1 Europe Biosimulation Market (2017-2032) by Product Type
- 6.1.1 Market Overview
- 6.1.2 Software
- 6.1.3 Services
- 6.2 Europe Biosimulation Market (2017-2032) by Application
- 6.2.1 Market Overview
- 6.2.2 Drug Development
- 6.2.3 Drug Discovery
- 6.2.4 Other Applications
- 6.3 Europe Biosimulation Market (2017-2032) by Delivery Type
- 6.3.1 Market Overview
- 6.3.2 Subscription Model
- 6.3.3 Ownership Model
- 6.4 Europe Biosimulation Market (2017-2032) by End User
- 6.4.1 Market Overview
- 6.4.2 Biotechnology & Pharmaceutical Companies
- 6.4.3 Research Institutes
- 6.4.4 Regulatory Authorities
- 6.4.5 Contract Research Organizations
- 6.5 Europe Biosimulation Market (2017-2032) by Country
- 6.5.1 Market Overview
- 6.5.2 United Kingdom
- 6.5.3 Germany
- 6.5.4 France
- 6.5.5 Italy
- 7 United Kingdom Biosimulation Market (2017-2032)
- 7.1 United Kingdom Biosimulation Market (2017-2032) by Product Type
- 7.1.1 Market Overview
- 7.1.2 Software
- 7.1.3 Services
- 7.2 United Kingdom Biosimulation Market (2017-2032) by Application
- 7.2.1 Market Overview
- 7.2.2 Drug Development
- 7.2.3 Drug Discovery
- 7.2.4 Other Application
- 7.3 United Kingdom Biosimulation Market (2017-2032) by Delivery Type
- 7.3.1 Market Overview
- 7.3.2 Subscription Model
- 7.3.3 Ownership Model
- 7.4 United Kingdom Biosimulation Market (2017-2032) by End User
- 7.4.1 Market Overview
- 7.4.2 Biotechnology & Pharmaceutical Companies
- 7.4.3 Research Institutes
- 7.4.4 Regulatory Authorities
- 7.4.5 Contract Research Organizations
- 8 Germany Biosimulation Market (2017-2032)
- 8.1 Germany Biosimulation Market (2017-2032) by Product Type
- 8.1.1 Market Overview
- 8.1.2 Software
- 8.1.3 Services
- 8.2 Germany Biosimulation Market (2017-2032) by Application
- 8.2.1 Market Overview
- 8.2.2 Drug Development
- 8.2.3 Drug Discovery
- 8.2.4 Other Application
- 8.3 Germany Biosimulation Market (2017-2032) by Delivery Type
- 8.3.1 Market Overview
- 8.3.2 Subscription Model
- 8.3.3 Ownership Model
- 8.4 Germany Biosimulation Market (2017-2032) by End User
- 8.4.1 Market Overview
- 8.4.2 Biotechnology & Pharmaceutical Companies
- 8.4.3 Research Institutes
- 8.4.4 Regulatory Authorities
- 8.4.5 Contract Research Organizations
- 9 France Biosimulation Market (2017-2032)
- 9.1 France Biosimulation Market (2017-2032) by Product Type
- 9.1.1 Market Overview
- 9.1.2 Software
- 9.1.3 Services
- 9.2 France Biosimulation Market (2017-2032) by Application
- 9.2.1 Market Overview
- 9.2.2 Drug Development
- 9.2.3 Drug Discovery
- 9.2.4 Other Application
- 9.3 France Biosimulation Market (2017-2032) by Delivery Type
- 9.3.1 Market Overview
- 9.3.2 Subscription Model
- 9.3.3 Ownership Model
- 9.4 France Biosimulation Market (2017-2032) by End User
- 9.4.1 Market Overview
- 9.4.2 Biotechnology & Pharmaceutical Companies
- 9.4.3 Research Institutes
- 9.4.4 Regulatory Authorities
- 9.4.5 Contract Research Organizations
- 10 Italy Biosimulation Market (2017-2032)
- 10.1 Italy Biosimulation Market (2017-2032) by Product Type
- 10.1.1 Market Overview
- 10.1.2 Software
- 10.1.3 Services
- 10.2 Italy Biosimulation Market (2017-2032) by Application
- 10.2.1 Market Overview
- 10.2.2 Drug Development
- 10.2.3 Drug Discovery
- 10.2.4 Other Application
- 10.3 Italy Biosimulation Market (2017-2032) by Delivery Type
- 10.3.1 Market Overview
- 10.3.2 Subscription Model
- 10.3.3 Ownership Model
- 10.4 Italy Biosimulation Market (2017-2032) by End User
- 10.4.1 Market Overview
- 10.4.2 Biotechnology & Pharmaceutical Companies
- 10.4.3 Research Institutes
- 10.4.4 Regulatory Authorities
- 10.4.5 Contract Research Organizations
- 11 Regulatory Framework
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication Year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by Year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by Departments
- 13.7 Analysis by Recipient Organization
- 14 Funding and Investment Analysis
- 14.1 Analysis by Funding Instances
- 14.2 Analysis by Type of Funding
- 14.3 Analysis by Funding Amount
- 14.4 Analysis by Leading Players
- 14.5 Analysis by Leading Investors
- 14.6 Analysis by Geography
- 15 Partnership and Collaborations Analysis
- 15.1 Analysis by Partnership Instances
- 15.2 Analysis by Type of Partnership
- 15.3 Analysis by Leading Players
- 15.4 Analysis by Geography
- 16 Supplier Landscape
- 16.1 Market Share by Top 5 Companies
- 16.2 Dassault Systèmes
- 16.2.1 Financial Analysis
- 16.2.2 Product Portfolio
- 16.2.3 Demographic Reach and Achievements
- 16.2.4 Mergers and Acquisitions
- 16.2.5 Certifications
- 16.3 Schrödinger
- 16.3.1 Financial Analysis
- 16.3.2 Product Portfolio
- 16.3.3 Demographic Reach and Achievements
- 16.3.4 Mergers and Acquisitions
- 16.3.5 Certifications
- 16.4 Physiomics Plc
- 16.4.1 Financial Analysis
- 16.4.2 Product Portfolio
- 16.4.3 Demographic Reach and Achievements
- 16.4.4 Mergers and Acquisitions
- 16.4.5 Certifications
- 16.5 Simulations Plus
- 16.5.1 Financial Analysis
- 16.5.2 Product Portfolio
- 16.5.3 Demographic Reach and Achievements
- 16.5.4 Mergers and Acquisitions
- 16.5.5 Certifications
- 16.6 Insilico Biotechnology
- 16.6.1 Financial Analysis
- 16.6.2 Product Portfolio
- 16.6.3 Demographic Reach and Achievements
- 16.6.4 Mergers and Acquisitions
- 16.6.5 Certifications
- 16.7 Genedata
- 16.7.1 Financial Analysis
- 16.7.2 Product Portfolio
- 16.7.3 Demographic Reach and Achievements
- 16.7.4 Mergers and Acquisitions
- 16.7.5 Certifications
- 16.8 Argenx
- 16.8.1 Financial Analysis
- 16.8.2 Product Portfolio
- 16.8.3 Demographic Reach and Achievements
- 16.8.4 Mergers and Acquisitions
- 16.8.5 Certifications
- 16.9 CureVac SE
- 16.9.1 Financial Analysis
- 16.9.2 Product Portfolio
- 16.9.3 Demographic Reach and Achievements
- 16.9.4 Mergers and Acquisitions
- 16.9.5 Certifications
- 16.10 INOSIM Software GmbH
- 16.10.1 Financial Analysis
- 16.10.2 Product Portfolio
- 16.10.3 Demographic
- 16.10.4 Mergers and Acquisitions
- 16.10.5 Certifications
- 16.11 Certara
- 16.11.1 Financial Analysis
- 16.11.2 Product Portfolio
- 16.11.3 Demographic Reach and Achievements
- 16.11.4 Mergers and Acquisitions
- 16.11.5 Certifications
- 17 Europe Biosimulation Market – Distribution Model (Additional Insight)
- 17.1 Overview
- 17.2 Potential Distributors
- 17.3 Key Parameters for Distribution Partner Assessment
- 18 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 19 Company Competitiveness Analysis (Additional Insight)
- 19.1 Very Small Companies
- 19.2 Small Companies
- 19.3 Mid-Sized Companies
- 19.4 Large Companies
- 19.5 Very Large Companies
- 20 Payment Methods (Additional Insight)
- 20.1 Government Funded
- 20.2 Private Insurance
- 20.3 Out-of-Pocket
- *Additional insights provided are customisable as per client requirements.
- * The coverage of the Market Landscape section depends on the data availability and may cover a minimum of 80% of the total market. The EMR team strives to make this section as comprehensive as possible.
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.